Oncolytic viruses (OVs) encoding a variety of transgenes have been evaluated as therapeutic tools to increase the efficacy of chimeric antigen receptor (CAR)–modified T cells in the solid tumor microenvironment (TME). Here, using systemically delivered OVs and CAR T cells in immunocompetent mouse models, we have defined a mechanism by which OVs can potentiate CAR T cell efficacy against solid tumor models of melanoma and glioma. We show that stimulation of the native T cell receptor (TCR) with viral or virally encoded epitopes gives rise to enhanced proliferation, CAR-directed antitumor function, and distinct memory phenotypes. In vivo expansion of dual-specific (DS) CAR T cells was leveraged by in vitro preloading with oncolytic vesicular stomatitis virus (VSV) or reovirus, allowing for a further in vivo expansion and reactivation of T cells by homologous boosting. This treatment led to prolonged survival of mice with subcutaneous melanoma and intracranial glioma tumors. Human CD19 CAR T cells could also be expanded in vitro with TCR reactivity against viral or virally encoded antigens and was associated with greater CAR-directed cytokine production. Our data highlight the utility of combining OV and CAR T cell therapy and show that stimulation of the native TCR can be exploited to enhance CAR T cell activity and efficacy in mice.
Purpose: Intravenous delivery of oncolytic viruses often leads to tumor vascular shutdown, resulting in decreased tumor perfusion and elevated tumor hypoxia. We hypothesized that using 3TSR to normalize tumor vasculature prior to administration of an oncolytic Newcastle disease virus (NDV) would enhance virus delivery and trafficking of immunologic cell subsets to the tumor core, resulting in systemically enhanced immunotherapy and regression of advanced-stage epithelial ovarian cancer (EOC). Experimental Design: Using an orthotopic, syngeneic mouse model of advanced-stage EOC, we pretreated mice with 3TSR (4 mg/kg per day) alone or followed by combination with fusogenic NDV(F3aa) (1.0 × 108 plaque-forming units). Results: Treatment with 3TSR normalized tumor vasculature, enhanced blood perfusion of primary EOC tumors, and induced disease regression. Animals treated with combination therapy had the greatest reduction in primary tumor mass, ascites accumulation, and secondary lesions (50% of mice were completely devoid of peritoneal metastases). Combining 3TSR + NDV(F3aa) led to enhanced trafficking of immunologic cells into the primary tumor core. Conclusions: We have shown, for the first time, that NDV, like other oncolytic viruses, is a potent mediator of acute vascular shutdown and that preventing this through vascular normalization can promote regression in a preclinical model of advanced-stage ovarian cancer. This challenges the current focus on induction of intravascular thrombosis as a requisite for successful oncolytic virotherapy. See related commentary by Bykov and Zamarin, p. 1446
In our clinical trials of oncolytic vesicular stomatitis virus expressing interferon beta (VSV-IFNβ), several patients achieved initial responses followed by aggressive relapse. We show here that VSV-IFNβ-escape tumors predictably express a point-mutated CSDE1P5S form of the RNA-binding Cold Shock Domain-containing E1 protein, which promotes escape as an inhibitor of VSV replication by disrupting viral transcription. Given time, VSV-IFNβ evolves a compensatory mutation in the P/M Inter-Genic Region which rescues replication in CSDE1P5S cells. These data show that CSDE1 is a major cellular co-factor for VSV replication. However, CSDE1P5S also generates a neo-epitope recognized by non-tolerized T cells. We exploit this predictable neo-antigenesis to drive, and trap, tumors into an escape phenotype, which can be ambushed by vaccination against CSDE1P5S, preventing tumor escape. Combining frontline therapy with escape-targeting immunotherapy will be applicable across multiple therapies which drive tumor mutation/evolution and simultaneously generate novel, targetable immunopeptidomes associated with acquired treatment resistance.
Supplementary Data Figure 2 Supplementary Data, Figure 2. ID8, CAOV-3 and NOSE cells were infected or mock infected (1x PBS) at an MOI of 0.1. Infected and uninfected cells were collected 24 hours later and stained for Annexin V a marker for early apoptosis and 7-Aminoactinomycin D (7AAD) a marker for dead cells (N=3). A, The cytogram of the four quadrants was used to distinguish normal (Annexin Vâ^'/7AAD+), early apoptotic (Annexin V+/7AADâ^'), late apoptotic (Annexin V+/7AAD+), and necrotic cells (Annexin Vâ^'/7AAD+). B, The sum of early and late apoptosis was presented as total apoptosis. Means +/- SEM are shown. Data were analyzed by 2way analysis of variance with Sidak's multiple comparison test; **,P<0.01 (N=3).
Supplementary Figure 1 Supplementary Data, Figure 1. Combination therapy results in decreased ascites fluid volume. At euthanasia, ascites fluid was aspirated from the abdomen of control and treated mice and the volume was quantified. Combined treatment with 3TSR and NDV(F3aa) resulted in a significant reduction in ascites volume compared to controls or other treatment groups. Means+/- SEM are shown. Data represents results from N=12 animals per experimental group. Data were analyzed by one-way analysis of variance with Tukey's multiple comparison test; *P<0.05.
Supplementary Figure 1 Supplementary Data, Figure 1. Combination therapy results in decreased ascites fluid volume. At euthanasia, ascites fluid was aspirated from the abdomen of control and treated mice and the volume was quantified. Combined treatment with 3TSR and NDV(F3aa) resulted in a significant reduction in ascites volume compared to controls or other treatment groups. Means+/- SEM are shown. Data represents results from N=12 animals per experimental group. Data were analyzed by one-way analysis of variance with Tukey's multiple comparison test; *P<0.05.